This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of hum... See more...

Aliases for TP53 Gene

Aliases for TP53 Gene

  • Tumor Protein P53 2 3 5
  • Cellular Tumor Antigen P53 3 4
  • Phosphoprotein P53 3 4
  • Antigen NY-CO-13 3 4
  • P53 3 4
  • Transformation-Related Protein 53 3
  • Mutant Tumor Protein 53 3
  • P53 Tumor Suppressor 3
  • Tumor Suppressor P53 4
  • Li-Fraumeni Syndrome 2
  • Tumor Supressor P53 3
  • Tumor Protein 53 3
  • BMFS5 3
  • TRP53 3
  • BCC7 3
  • LFS1 3

External Ids for TP53 Gene

Previous GeneCards Identifiers for TP53 Gene

  • GC17P008026
  • GC17M008311
  • GC17M007514
  • GC17M007772
  • GC17M007512
  • GC17M007565
  • GC17M007465

Summaries for TP53 Gene

Entrez Gene Summary for TP53 Gene

  • This gene encodes a tumor suppressor protein containing transcriptional activation, DNA binding, and oligomerization domains. The encoded protein responds to diverse cellular stresses to regulate expression of target genes, thereby inducing cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. Mutations in this gene are associated with a variety of human cancers, including hereditary cancers such as Li-Fraumeni syndrome. Alternative splicing of this gene and the use of alternate promoters result in multiple transcript variants and isoforms. Additional isoforms have also been shown to result from the use of alternate translation initiation codons from identical transcript variants (PMIDs: 12032546, 20937277). [provided by RefSeq, Dec 2016]

CIViC Summary for TP53 Gene

  • TP53 mutations are universal across cancer types. The loss of a tumor suppressor is most often through large deleterious events, such as frameshift mutations, or premature stop codons. In TP53 however, many of the observed mutations in cancer are found to be single nucleotide missense variants. These variants are broadly distributed throughout the gene, but with the majority localizing in the DNA binding domain. There is no single hotspot in the DNA binding domain, but a majority of mutations occur in amino acid positions 175, 245, 248, 273, and 282 (NM_000546) (Olivier et al., 2010). To fulfill its proper biological function four TP53 polypeptides must form a tetramer which functions as a transcription factor, therefore even if one out of four polypeptides has inactivating mutation it may lead to dominant negative phenotype of variable degree. While a large proportion of cancer genomics research is focused on somatic variants, TP53 is also of note in the germline. Germline TP53 mutations are the hallmark of Li-Fraumeni syndrome, and many (both germline and somatic) variants have been found to have a prognostic impact on patient outcomes. The significance of many polymorphisms for susceptibility and prognosis of disease is still very much up for debate.

GeneCards Summary for TP53 Gene

TP53 (Tumor Protein P53) is a Protein Coding gene. Diseases associated with TP53 include Li-Fraumeni Syndrome and Osteogenic Sarcoma. Among its related pathways are DNA Double-Strand Break Repair and Wnt Signaling Pathway and Pluripotency. Gene Ontology (GO) annotations related to this gene include DNA-binding transcription factor activity and protein heterodimerization activity. An important paralog of this gene is TP73.

UniProtKB/Swiss-Prot Summary for TP53 Gene

  • Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER2 (PubMed:24051492).

Tocris Summary for TP53 Gene

  • p53 (TP53) is a transcription factor whose protein levels and post-translational modification state alter in response to cellular stress (e.g. hypoxia, DNA and spindle damage). Activation of p53 occurs by several mechanisms including phosphorylation by ATM, ATR, Chk1 and MAPKs.

Gene Wiki entry for TP53 Gene

Additional gene information for TP53 Gene

No data available for PharmGKB "VIP" Summary , Rfam classification and piRNA Summary for TP53 Gene

Genomics for TP53 Gene

GeneHancer (GH) Regulatory Elements for TP53 Gene

Promoters and enhancers for TP53 Gene
- Elite GeneHancer and/or Elite GeneHancer-gene association Download GeneHancer data from 2017 publication | Request up-to-date GeneHancer data (full dataset)

GeneHancers around TP53 on UCSC Golden Path with GeneCards custom track

Top Transcription factor binding sites by QIAGEN in the TP53 gene promoter:
  • ARP-1
  • C/EBPbeta
  • CREB
  • Sp1

Genomic Locations for TP53 Gene

Genomic Locations for TP53 Gene
chr17:7,661,779-7,687,550
(GRCh38/hg38)
Size:
25,772 bases
Orientation:
Minus strand
chr17:7,565,097-7,590,863
(GRCh37/hg19)
Size:
25,767 bases
Orientation:
Minus strand

Genomic View for TP53 Gene

Genes around TP53 on UCSC Golden Path with GeneCards custom track

Cytogenetic band:
TP53 Gene in genomic location: bands according to Ensembl, locations according to GeneLoc (and/or Entrez Gene and/or Ensembl if different)
Genomic Location for TP53 Gene
GeneLoc Logo Genomic Neighborhood Exon StructureGene Density

RefSeq DNA sequence for TP53 Gene

Proteins for TP53 Gene

  • Protein details for TP53 Gene (UniProtKB/Swiss-Prot)

    Protein Symbol:
    P04637-P53_HUMAN
    Recommended name:
    Cellular tumor antigen p53
    Protein Accession:
    P04637
    Secondary Accessions:
    • Q15086
    • Q15087
    • Q15088
    • Q16535
    • Q16807
    • Q16808
    • Q16809
    • Q16810
    • Q16811
    • Q16848
    • Q2XN98
    • Q3LRW1
    • Q3LRW2
    • Q3LRW3
    • Q3LRW4
    • Q3LRW5
    • Q86UG1
    • Q8J016
    • Q99659
    • Q9BTM4
    • Q9HAQ8
    • Q9NP68
    • Q9NPJ2
    • Q9NZD0
    • Q9UBI2
    • Q9UQ61

    Protein attributes for TP53 Gene

    Size:
    393 amino acids
    Molecular mass:
    43653 Da
    Cofactor:
    Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
    Quaternary structure:
    • Forms homodimers and homotetramers (PubMed:19011621). Binds DNA as a homotetramer. Interacts with AXIN1. Probably part of a complex consisting of TP53, HIPK2 and AXIN1 (By similarity). Interacts with histone acetyltransferases EP300 and methyltransferases HRMT1L2 and CARM1, and recruits them to promoters. Interacts (via C-terminus) with TAF1; when TAF1 is part of the TFIID complex. Interacts with ING4; this interaction may be indirect. Found in a complex with CABLES1 and TP73. Interacts with HIPK1, HIPK2, and TP53INP1. Interacts with WWOX. May interact with HCV core protein. Interacts with USP7 and SYVN1. Interacts with HSP90AB1. Interacts with CHD8; leading to recruit histone H1 and prevent transactivation activity (By similarity). Interacts with ARMC10, BANP, CDKN2AIP, NUAK1, STK11/LKB1, UHRF2 and E4F1. Interacts with YWHAZ; the interaction enhances TP53 transcriptional activity. Phosphorylation of YWHAZ on 'Ser-58' inhibits this interaction. Interacts (via DNA-binding domain) with MAML1 (via N-terminus). Interacts with MKRN1. Interacts with PML (via C-terminus). Interacts with MDM2; leading to ubiquitination and proteasomal degradation of TP53. Directly interacts with FBXO42; leading to ubiquitination and degradation of TP53. Interacts (phosphorylated at Ser-15 by ATM) with the phosphatase PP2A-PPP2R5C holoenzyme; regulates stress-induced TP53-dependent inhibition of cell proliferation. Interacts with PPP2R2A. Interacts with AURKA, DAXX, BRD7 and TRIM24. Interacts (when monomethylated at Lys-382) with L3MBTL1. Isoform 1 interacts with isoform 2 and with isoform 4. Interacts with GRK5. Binds to the CAK complex (CDK7, cyclin H and MAT1) in response to DNA damage. Interacts with CDK5 in neurons. Interacts with AURKB, SETD2, UHRF2 and NOC2L. Interacts (via N-terminus) with PTK2/FAK1; this promotes ubiquitination by MDM2. Interacts with PTK2B/PYK2; this promotes ubiquitination by MDM2. Interacts with PRKCG. Interacts with PPIF; the association implicates preferentially tetrameric TP53, is induced by oxidative stress and is impaired by cyclosporin A (CsA). Interacts with SNAI1; the interaction induces SNAI1 degradation via MDM2-mediated ubiquitination and inhibits SNAI1-induced cell invasion. Interacts with KAT6A. Interacts with UBC9. Interacts with ZNF385B; the interaction is direct. Interacts (via DNA-binding domain) with ZNF385A; the interaction is direct and enhances p53/TP53 transactivation functions on cell-cycle arrest target genes, resulting in growth arrest. Interacts with ANKRD2. Interacts with RFFL and RNF34; involved in p53/TP53 ubiquitination. Interacts with MTA1 and COP1. Interacts with CCAR2 (via N-terminus). Interacts with MORC3 (PubMed:17332504). Interacts (via C-terminus) with POU4F2 isoform 1 (via C-terminus) (PubMed:17145718). Interacts (via oligomerization region) with NOP53; the interaction is direct and may prevent the MDM2-mediated proteasomal degradation of TP53 (PubMed:22522597). Interacts with AFG1L; mediates mitochondrial translocation of TP53 (PubMed:27323408). Interacts with UBD (PubMed:25422469). Interacts with TAF6 isoform 1 and isoform 4 (PubMed:20096117). Interacts with C10orf90/FATS; the interaction inhibits binding of TP53 and MDM2 (By similarity). Interacts with NUPR1; interaction is stress-dependent (PubMed:18690848). Forms a complex with EP300 and NUPR1; this complex binds CDKN1A promoter leading to transcriptional induction of CDKN1A (PubMed:18690848). Interacts with PRMT5 in response to DNA damage; the interaction is STRAP dependent (PubMed:19011621).
    • (Microbial infection) Interacts with cancer-associated/HPV E6 viral proteins leading to ubiquitination and degradation of TP53 giving a possible model for cell growth regulation. This complex formation requires an additional factor, E6-AP, which stably associates with TP53 in the presence of E6.
    • (Microbial infection) Interacts with human cytomegalovirus/HHV-5 protein UL123.
    • (Microbial infection) Interacts (via N-terminus) with human adenovirus 5 E1B-55K protein; this interaction leads to the inhibition of TP53 function and/or its degradation.

    Three dimensional structures from OCA and Proteopedia for TP53 Gene

    Alternative splice isoforms for TP53 Gene

neXtProt entry for TP53 Gene

Post-translational modifications for TP53 Gene

  • Acetylated. Acetylation of Lys-382 by CREBBP enhances transcriptional activity. Deacetylation of Lys-382 by SIRT1 impairs its ability to induce proapoptotic program and modulate cell senescence. Deacetylation by SIRT2 impairs its ability to induce transcription activation in a AKT-dependent manner.
  • Phosphorylation on Ser residues mediates transcriptional activation. Phosphorylated by HIPK1 (By similarity). Phosphorylation at Ser-9 by HIPK4 increases repression activity on BIRC5 promoter. Phosphorylated on Thr-18 by VRK1. Phosphorylated on Ser-20 by CHEK2 in response to DNA damage, which prevents ubiquitination by MDM2. Phosphorylated on Ser-20 by PLK3 in response to reactive oxygen species (ROS), promoting p53/TP53-mediated apoptosis. Phosphorylated on Thr-55 by TAF1, which promotes MDM2-mediated degradation. Phosphorylated on Ser-33 by CDK7 in a CAK complex in response to DNA damage. Phosphorylated on Ser-46 by HIPK2 upon UV irradiation. Phosphorylation on Ser-46 is required for acetylation by CREBBP. Phosphorylated on Ser-392 following UV but not gamma irradiation. Phosphorylated on Ser-15 upon ultraviolet irradiation; which is enhanced by interaction with BANP. Phosphorylated by NUAK1 at Ser-15 and Ser-392; was initially thought to be mediated by STK11/LKB1 but it was later shown that it is indirect and that STK11/LKB1-dependent phosphorylation is probably mediated by downstream NUAK1 (PubMed:21317932). It is unclear whether AMP directly mediates phosphorylation at Ser-15. Phosphorylated on Thr-18 by isoform 1 and isoform 2 of VRK2. Phosphorylation on Thr-18 by isoform 2 of VRK2 results in a reduction in ubiquitination by MDM2 and an increase in acetylation by EP300. Stabilized by CDK5-mediated phosphorylation in response to genotoxic and oxidative stresses at Ser-15, Ser-33 and Ser-46, leading to accumulation of p53/TP53, particularly in the nucleus, thus inducing the transactivation of p53/TP53 target genes. Phosphorylated by DYRK2 at Ser-46 in response to genotoxic stress. Phosphorylated at Ser-315 and Ser-392 by CDK2 in response to DNA-damage.
  • Dephosphorylated by PP2A-PPP2R5C holoenzyme at Thr-55. SV40 small T antigen inhibits the dephosphorylation by the AC form of PP2A.
  • May be O-glycosylated in the C-terminal basic region. Studied in EB-1 cell line.
  • Ubiquitinated by MDM2 and SYVN1, which leads to proteasomal degradation (PubMed:10722742, PubMed:12810724, PubMed:15340061, PubMed:17170702, PubMed:19880522). Ubiquitinated by RFWD3, which works in cooperation with MDM2 and may catalyze the formation of short polyubiquitin chains on p53/TP53 that are not targeted to the proteasome (PubMed:10722742, PubMed:12810724, PubMed:20173098). Ubiquitinated by MKRN1 at Lys-291 and Lys-292, which leads to proteasomal degradation (PubMed:19536131). Deubiquitinated by USP10, leading to its stabilization (PubMed:20096447). Ubiquitinated by TRIM24, RFFL, RNF34 and RNF125, which leads to proteasomal degradation (PubMed:19556538). Ubiquitination by TOPORS induces degradation (PubMed:19473992). Deubiquitination by USP7, leading to stabilization (PubMed:15053880). Isoform 4 is monoubiquitinated in an MDM2-independent manner (PubMed:15340061). Ubiquitinated by COP1, which leads to proteasomal degradation (PubMed:19837670). Ubiquitination and subsequent proteasomal degradation is negatively regulated by CCAR2 (PubMed:25732823). Polyubiquitinated by C10orf90/FATS, polyubiquitination is 'Lys-48'-linkage independent and non-proteolytic, leading to TP53 stabilization (By similarity).
  • Monomethylated at Lys-372 by SETD7, leading to stabilization and increased transcriptional activation (PubMed:15525938, PubMed:16415881). Monomethylated at Lys-370 by SMYD2, leading to decreased DNA-binding activity and subsequent transcriptional regulation activity (PubMed:17108971). Lys-372 monomethylation prevents interaction with SMYD2 and subsequent monomethylation at Lys-370 (PubMed:17108971). Dimethylated at Lys-373 by EHMT1 and EHMT2 (PubMed:20118233). Monomethylated at Lys-382 by KMT5A, promoting interaction with L3MBTL1 and leading to repress transcriptional activity (PubMed:17707234). Dimethylation at Lys-370 and Lys-382 diminishes p53 ubiquitination, through stabilizing association with the methyl reader PHF20 (PubMed:22864287). Demethylation of dimethylated Lys-370 by KDM1A prevents interaction with TP53BP1 and represses TP53-mediated transcriptional activation (PubMed:17805299). Monomethylated at Arg-333 and dimethylated at Arg-335 and Arg-337 by PRMT5; methylation is increased after DNA damage and might possibly affect TP53 target gene specificity (PubMed:19011621).
  • Sumoylated with SUMO1. Sumoylated at Lys-386 by UBC9.
  • Ubiquitination at Lys164, Lys101, Lys132, Lys291, Lys292, Lys305, Lys320, and Lys321
  • Modification sites at PhosphoSitePlus

Antibody Products

No data available for DME Specific Peptides for TP53 Gene

Domains & Families for TP53 Gene

Gene Families for TP53 Gene

Human Protein Atlas (HPA):
  • Cancer-related genes
  • Disease related genes
  • Plasma proteins
  • Potential drug targets
  • Predicted intracellular proteins
  • Transcription factors
  • Transporters

Suggested Antigen Peptide Sequences for TP53 Gene

GenScript: Design optimal peptide antigens:
  • Tumor protein p53 (A2I9Y7_HUMAN)
  • Tumor protein p53 (A2I9Z0_HUMAN)
  • Tumor protein p53 (A2I9Z1_HUMAN)
  • Tumor protein p53 (A2I9Z2_HUMAN)
  • Cellular tumor antigen p53 (A4GW67_HUMAN)

Graphical View of Domain Structure for InterPro Entry

P04637

UniProtKB/Swiss-Prot:

P53_HUMAN :
  • The nuclear export signal acts as a transcriptional repression domain. The TADI and TADII motifs (residues 17 to 25 and 48 to 56) correspond both to 9aaTAD motifs which are transactivation domains present in a large number of yeast and animal transcription factors.
  • Belongs to the p53 family.
Domain:
  • The nuclear export signal acts as a transcriptional repression domain. The TADI and TADII motifs (residues 17 to 25 and 48 to 56) correspond both to 9aaTAD motifs which are transactivation domains present in a large number of yeast and animal transcription factors.
Family:
  • Belongs to the p53 family.
genes like me logo Genes that share domains with TP53: view

Function for TP53 Gene

Molecular function for TP53 Gene

UniProtKB/Swiss-Prot Function:
Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seems to have an effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. Regulates the circadian clock by repressing CLOCK-ARNTL/BMAL1-mediated transcriptional activation of PER2 (PubMed:24051492).
UniProtKB/Swiss-Prot Induction:
Up-regulated in response to DNA damage. Isoform 2 is not induced in tumor cells in response to stress.
GENATLAS Biochemistry:
tumor suppressor protein p53 required for G1 growth arrest by WAF1 (CDKN1A),following DNA damage or induction of apoptosis,also regulating a G2 checkpoint through cyclin B1,transcriptional activator through acetylation of transactivation site by CREBBP binding MDM2 resulting in transcriptional silencing and ubiquitin/proteasome dependent degradation of p53,activated by conjugation to UBL1 (SUMO1),putative up-regulated c-MYC target gene,putative teratologic suppressor gene and modulator of TFIIH (GTF2H),associated in nucleotide excision repair,activated by ATM in association with 14.3.3 proteins (YWHA*),tumor suppressor gene (see TSG17A),mutated in cancers such as pancreas and endometrial carcinomas,in Barrett's adenocarcinoma (and esophageal squamous cell carcinoma),in hepatocellular carcinoma with poor prognosis

Phenotypes From GWAS Catalog for TP53 Gene

Gene Ontology (GO) - Molecular Function for TP53 Gene

GO ID Qualified GO term Evidence PubMed IDs
GO:0000977 RNA polymerase II regulatory region sequence-specific DNA binding IEA --
GO:0000978 RNA polymerase II proximal promoter sequence-specific DNA binding IDA 24289924
GO:0000980 RNA polymerase II distal enhancer sequence-specific DNA binding ISS --
GO:0000981 DNA-binding transcription factor activity, RNA polymerase II-specific IDA,NAS 19274049
GO:0001046 core promoter sequence-specific DNA binding IDA 23629966
genes like me logo Genes that share ontologies with TP53: view

Phenotypes for TP53 Gene

MGI mutant phenotypes for TP53:
inferred from 78 alleles
GenomeRNAi human phenotypes for TP53:
genes like me logo Genes that share phenotypes with TP53: view

Human Phenotype Ontology for TP53 Gene

HPO Id HPO Name Alternative Ids Definition Synonyms

Animal Models for TP53 Gene

MGI Knock Outs for TP53:

CRISPR Products

miRNA for TP53 Gene

miRTarBase miRNAs that target TP53

Transcription Factor Targets for TP53 Gene

Selected GeneGlobe predicted Target genes for TP53
Targeted motifs for TP53 Gene
HOMER Transcription Factor Regulatory Elements motif TP53
  • Consensus sequence: AACATGCCCAGACATGCCCN Submotif: canonical Cell Type: Saos GEO ID: GSE15780

Clone Products

  • Addgene plasmids for TP53

No data available for Enzyme Numbers (IUBMB) for TP53 Gene

Localization for TP53 Gene

Subcellular locations from UniProtKB/Swiss-Prot for TP53 Gene

Cytoplasm. Nucleus. Nucleus, PML body. Endoplasmic reticulum. Mitochondrion matrix. Note=Interaction with BANP promotes nuclear localization (PubMed:15701641). Recruited into PML bodies together with CHEK2 (PubMed:12810724). Translocates to mitochondria upon oxidative stress (PubMed:22726440). Translocates to mitochondria in response to mitomycin C treatment (PubMed:27323408). {ECO:0000269 PubMed:12810724, ECO:0000269 PubMed:15701641, ECO:0000269 PubMed:22726440, ECO:0000269 PubMed:27323408}.
Isoform 1: Nucleus. Cytoplasm. Note=Predominantly nuclear but localizes to the cytoplasm when expressed with isoform 4.
Isoform 2: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.
Isoform 3: Nucleus. Cytoplasm. Note=Localized in the nucleus in most cells but found in the cytoplasm in some cells.
Isoform 4: Nucleus. Cytoplasm. Note=Predominantly nuclear but translocates to the cytoplasm following cell stress.
Isoform 7: Nucleus. Cytoplasm. Note=Localized mainly in the nucleus with minor staining in the cytoplasm.
Isoform 8: Nucleus. Cytoplasm. Note=Localized in both nucleus and cytoplasm in most cells. In some cells, forms foci in the nucleus that are different from nucleoli.
Isoform 9: Cytoplasm.

Subcellular locations from

COMPARTMENTS
Extracellular space Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi Apparatus Nucleus Mitochondrion 0 1 2 3 4 5 Confidence
COMPARTMENTS Subcellular localization image for TP53 gene
Compartment Confidence
mitochondrion 5
nucleus 5
cytosol 5
endoplasmic reticulum 4
extracellular 3
cytoskeleton 3
plasma membrane 2
lysosome 2
peroxisome 1
endosome 1
golgi apparatus 1

Subcellular locations from the

Human Protein Atlas (HPA)

Gene Ontology (GO) - Cellular Components for TP53 Gene

GO ID Qualified GO term Evidence PubMed IDs
GO:0000790 nuclear chromatin IDA 15710329
GO:0005634 nucleus IEA,IMP 16479015
GO:0005654 nucleoplasm IDA,TAS --
GO:0005657 replication fork IEA --
GO:0005667 transcription factor complex IGI 17145718
genes like me logo Genes that share ontologies with TP53: view

Pathways & Interactions for TP53 Gene

PathCards logo

SuperPathways for TP53 Gene